Invention Grant
- Patent Title: Substituted cyanopyrrolidines with activity as DUB inhibitors
-
Application No.: US16615709Application Date: 2018-06-19
-
Publication No.: US11059809B2Publication Date: 2021-07-13
- Inventor: Martin Lee Stockley , Mark Ian Kemp
- Applicant: MISSION THERAPEUTICS LIMITED
- Applicant Address: GB Cambridge
- Assignee: MISSION THERAPEUTICS LIMITED
- Current Assignee: MISSION THERAPEUTICS LIMITED
- Current Assignee Address: GB Cambridge
- Priority: GB1709824 20170620,GB1803561 20180306
- International Application: PCT/GB2018/051691 WO 20180619
- International Announcement: WO2018/234775 WO 20181227
- Main IPC: C07D403/12
- IPC: C07D403/12 ; A61P25/28 ; A61P35/00
Abstract:
The present invention relates to a class of substituted-cyanopyrrolidines of formula (Ia), (Ib), and (Ic), with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30), having utility in a variety of therapeutic areas including cancer and conditions involving mitochondrial dysfunction (Ia).
Public/Granted literature
- US20200172519A1 SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS DUB INHIBITORS Public/Granted day:2020-06-04
Information query
